Joseph G. Pressey · Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome
Follow
Article1 min read·Published Jan 2013Older

Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Jan 2013 · 1 min read

In brief

In brief

This case report describes successful treatment of a refractory segmental infantile hemangioma in a patient with PHACE syndrome using sirolimus after conventional therapies failed. The response to mTOR inhibition suggests a potential mechanistic role for mTOR signaling in hemangioma pathogenesis.

Written by the GCMD Library team from the article.

Joseph G. Pressey

Infantile hemangiomas (IHs) are common benign tumors of childhood. IHs often regress satisfactorily without intervention, but a subset of IHs may lead to functional or cosmetic morbidity necessitating therapy. PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas. We present an infant with PHACE syndrome and segmental IH that failed conventional first-line therapies. Treatment with sirolimus provided benefit with regression of the cutaneous IH. As an inhibitor of the mammalian target of rapamycin (mTOR) pathway, the effective use of sirolimus may shed light on the emerging role of mTOR signaling in the development and pathogenesis of IHs.

Statements in this article

  1. Infantile hemangiomas are common benign tumors of childhood.

    Established
  2. Infantile hemangiomas often regress satisfactorily without intervention.

    Established
  3. A subset of infantile hemangiomas may lead to functional or cosmetic morbidity necessitating therapy.

    Established
  4. PHACE syndrome is characterized by a variety of neurocutaneous and vascular anomalies that typically include segmental hemangiomas.

    Established
  5. Treatment with sirolimus provided benefit with regression of the cutaneous infantile hemangioma in a patient with PHACE syndrome who failed conventional first-line therapies.

    Research
  6. Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway.

    Established

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
Only a few other public items share this field — go deeper there →
GCMD Library — educational content from recorded physician discussions, not medical advice.